Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
250 participants
INTERVENTIONAL
2004-04-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
NCT00172042
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00070486
ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer
NCT00021008
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
NCT00020202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zometa®
4mg monthly for 12 months from date of first chemotherapy dose
zoledronic acid
Taxotere
Carboplatin
no further treatment
Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zoledronic acid
Taxotere
Carboplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery
* Women must not be pregnant or attempting to become pregnant
* Able and willing to sign informed consent
Exclusion Criteria
* Patients with cancer that has spread to the brain who are receiving treatment
* Patients with kidney disease
* Patients treated with other investigational drugs
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Consultants
Hoover, Alabama, United States
Arizona Oncology Assoc.
Tucson, Arizona, United States
NEA Clinic
Jonesboro, Arkansas, United States
Highlands Oncology Group
Springdale, Arkansas, United States
NorthBay Cancer Center
Fairfield, California, United States
UCLA
Los Angeles, California, United States
Clinical Trials and Research Associates, Inc.
Montebello, California, United States
Med. Oncology Care Associates
Orange, California, United States
Cancer Center of Santa Barbara
Santa Barbara, California, United States
Cancer Center of Colorado Springs
Colorado Springs, Colorado, United States
Northern Hematology-Oncology
Thornton, Colorado, United States
Lynn Regional Cancer Center
Boca Raton, Florida, United States
New Hope Cancer Centers
Hudson, Florida, United States
Oceola Cancer Center
Kissimmee, Florida, United States
VA Medical Center
Miami, Florida, United States
Innovative Medical Research of South Florida, Inc.
Miami Shores, Florida, United States
NCH Healthcare System Oncology Research
Naples, Florida, United States
Metcare Oncology
Ormond Beach, Florida, United States
Hematology-Oncology Associates
Pensacola, Florida, United States
AMIT SHAH Medical Group
Sebring, Florida, United States
Peachtree Hematology & Oncology
Atlanta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Straub Clinic & Hospital
Honolulu, Hawaii, United States
Kaiser Foundation Hospital
Honolulu, Hawaii, United States
Advocate Illinois Masonic Medical Center Creticos Cancer Center
Chicago, Illinois, United States
OSF Center for Cancer Care
Rockford, Illinois, United States
Springfield Clinic, LLP
Springfield, Illinois, United States
Central Indiana Cancer Centers
Indianapolis, Indiana, United States
Oncology Institute of Greater Lafayette
Lafayette, Indiana, United States
Community Hospital, Cancer Research Dept.
Munster, Indiana, United States
Northern Indiana Oncology Associates
South Bend, Indiana, United States
Cedar Valley Medical Specialists
Waterloo, Iowa, United States
Kansas City Cancer Ctr. South
Lenexa, Kansas, United States
Hematology/Oncology Clinic
Baton Rouge, Louisiana, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
LSU Health Sciences Center
Shreveport, Louisiana, United States
Maine Center for Cancer Medicine
Scarborough, Maine, United States
Oncology Care Associates
Bethesda, Maryland, United States
Berkshire Hematology Oncology PC
Pittsfield, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Kalamazoo Hematology & Oncology
Kalamazoo, Michigan, United States
Mitchell Folbe, MD, PC
Troy, Michigan, United States
Park Nicollett Institute
Saint Louis Park, Minnesota, United States
St. Louis Cancer Care
Chesterfield, Missouri, United States
Southeast Nebraska Cancer Center
Lincoln, Nebraska, United States
Odyssey Research
Scottsbluff, Nebraska, United States
Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Nevada Cancer Center
Las Vegas, Nevada, United States
East Orange VA Medical System
East Orange, New Jersey, United States
Howell Office Plaza
Howell Township, New Jersey, United States
Atlantic Hem Onc Associates, LLC
Manasquan, New Jersey, United States
Hematology/Oncology Assoc. of South Jersey
Mount Holly, New Jersey, United States
Cancer Institute of New Jersey at Cooper University Hospital
Voorhees Township, New Jersey, United States
New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico, United States
San Juan Regional Cancer Ctr.
Farmington, New Mexico, United States
New Mexico Cancer Care Associates
Santa Fe, New Mexico, United States
Engracio Cortes, MD
Bayside, New York, United States
Arena Oncology Assoc.
Great Neck, New York, United States
James P. Wilmot Cancer Center
Rochester, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Syracuse VA Medical Center
Syracuse, New York, United States
Presbyterian Hospital
Charlotte, North Carolina, United States
Southern Oncology Research
Grifton, North Carolina, United States
Barberton Citizens Hospital-Cancer Center
Barberton, Ohio, United States
Dayton Clinical Oncology Program
Dayton, Ohio, United States
Forum Health Cancer CareCenter
Youngstown, Ohio, United States
Cancer Specialists of Oklahoma
Oklahoma City, Oklahoma, United States
Hematology Oncology Associates
Medford, Oregon, United States
Charleston Hematology Oncology
Charleston, South Carolina, United States
Charleston Cancer Center
Charleston, South Carolina, United States
Liberty Hematology-Oncology
Columbia, South Carolina, United States
Santee Hematology/Oncology
Sumter, South Carolina, United States
The Jones Clinic
Germantown, Tennessee, United States
Knoxville Cancer Center
Knoxville, Tennessee, United States
Cancer Specialists of South Texas
Corpus Christi, Texas, United States
Blood and Cancer Center of East Texas
Tyler, Texas, United States
Tyler Hematology Oncology, PA
Tyler, Texas, United States
Odyssey Research
Belle Haven, Virginia, United States
Masoom Kandahari, MD
Woodbridge, Virginia, United States
West Virginia University
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer. 2010 Mar;67(3):330-8. doi: 10.1016/j.lungcan.2009.04.020. Epub 2009 Jun 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US 75
Identifier Type: -
Identifier Source: secondary_id
CZOL446EUS75
Identifier Type: -
Identifier Source: org_study_id
NCT00093717
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.